{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:52:08Z","timestamp":1790693528531,"version":"4.1.0"},"reference-count":47,"publisher":"American Association for Cancer Research (AACR)","issue":"4","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In most patients with chronic myeloid leukemia (CML), the disease can be kept under control using the BCR\/ABL kinase inhibitor imatinib. Nevertheless, resistance or intolerance to imatinib and other BCR\/ABL inhibitors may occur during therapy. Therefore, CML research is focusing on novel targets and targeted drugs. Polo-like kinase 1 (Plk1) is a serine\/threonine kinase that plays an essential role in mitosis. In this study, we examined the expression of Plk1 in CML cells and its potential role as a therapeutic target. Plk1 was found to be expressed in phosphorylated form in the CML cell line K562 as well as in primary CML cells in all patients tested. Inhibition of BCR\/ABL by imatinib or nilotinib (AMN107) led to decreased expression of the Plk1 protein in CML cells, suggesting that BCR\/ABL promotes Plk1 generation. Silencing of Plk1 in CML cells by a small interfering RNA approach was followed by cell cycle arrest and apoptosis. Furthermore, the Plk1-targeting drug BI 2536 was found to inhibit proliferation of imatinib-sensitive and imatinib-resistant CML cells, including leukemic cells, carrying the T315 mutation of BCR\/ABL with reasonable IC50 values (1\u201350 nmol\/L). The growth-inhibitory effects of BI 2536 on CML cells were found to be associated with cell cycle arrest and apoptosis. Moreover, BI 2536 was found to synergize with imatinib and nilotinib in producing growth inhibition in CML cells. In conclusion, Plk1 is expressed in CML cells and may represent a novel, interesting target in imatinib-sensitive and imatinib-resistant CML. Cancer Res; 70(4); 1513\u201323<\/jats:p>","DOI":"10.1158\/0008-5472.can-09-2181","type":"journal-article","created":{"date-parts":[[2010,2,10]],"date-time":"2010-02-10T00:07:31Z","timestamp":1265760451000},"page":"1513-1523","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Polo-like Kinase 1 (Plk1) as a Novel Drug Target in Chronic Myeloid Leukemia: Overriding Imatinib Resistance with the Plk1 Inhibitor BI 2536"],"prefix":"10.1158","volume":"70","author":[{"given":"Karoline V.","family":"Gleixner","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Internal Medicine I, Division of Hematology and Hemostaseology, 2Institute of Immunology, 3Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna; 4Department of Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine; 5Ludwig Boltzmann Cluster Oncology, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Ferenc","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Internal Medicine I, Division of Hematology and Hemostaseology, 2Institute of Immunology, 3Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna; 4Department of Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine; 5Ludwig Boltzmann Cluster Oncology, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Peter","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Internal Medicine I, Division of Hematology and Hemostaseology, 2Institute of Immunology, 3Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna; 4Department of Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine; 5Ludwig Boltzmann Cluster Oncology, Vienna, Austria"},{"name":"Authors' Affiliations:\u20081Department of Internal Medicine I, Division of Hematology and Hemostaseology, 2Institute of Immunology, 3Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna; 4Department of Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine; 5Ludwig Boltzmann Cluster Oncology, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Gruze","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Internal Medicine I, Division of Hematology and Hemostaseology, 2Institute of Immunology, 3Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna; 4Department of Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine; 5Ludwig Boltzmann Cluster Oncology, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata A.","family":"Meyer","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Internal Medicine I, Division of Hematology and Hemostaseology, 2Institute of Immunology, 3Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna; 4Department of Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine; 5Ludwig Boltzmann Cluster Oncology, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emir","family":"Hadzijusufovic","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Internal Medicine I, Division of Hematology and Hemostaseology, 2Institute of Immunology, 3Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna; 4Department of Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine; 5Ludwig Boltzmann Cluster Oncology, Vienna, Austria"},{"name":"Authors' Affiliations:\u20081Department of Internal Medicine I, Division of Hematology and Hemostaseology, 2Institute of Immunology, 3Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna; 4Department of Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine; 5Ludwig Boltzmann Cluster Oncology, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Cerny-Reiterer","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Internal Medicine I, Division of Hematology and Hemostaseology, 2Institute of Immunology, 3Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna; 4Department of Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine; 5Ludwig Boltzmann Cluster Oncology, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Mayerhofer","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Internal Medicine I, Division of Hematology and Hemostaseology, 2Institute of Immunology, 3Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna; 4Department of Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine; 5Ludwig Boltzmann Cluster Oncology, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried F.","family":"Pickl","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Internal Medicine I, Division of Hematology and Hemostaseology, 2Institute of Immunology, 3Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna; 4Department of Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine; 5Ludwig Boltzmann Cluster Oncology, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Sillaber","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Internal Medicine I, Division of Hematology and Hemostaseology, 2Institute of Immunology, 3Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna; 4Department of Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine; 5Ludwig Boltzmann Cluster Oncology, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Internal Medicine I, Division of Hematology and Hemostaseology, 2Institute of Immunology, 3Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna; 4Department of Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine; 5Ludwig Boltzmann Cluster Oncology, Vienna, Austria"},{"name":"Authors' Affiliations:\u20081Department of Internal Medicine I, Division of Hematology and Hemostaseology, 2Institute of Immunology, 3Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna; 4Department of Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine; 5Ludwig Boltzmann Cluster Oncology, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2010,2,14]]},"reference":[{"key":"2022061702454645300_bib1","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"2022061702454645300_bib2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/1-4020-7847-1_12","article-title":"Signal transduction pathways in Bcr-Abl transformed cells","volume":"119","author":"Arlinghaus","year":"2004","journal-title":"Cancer Treat Res"},{"key":"2022061702454645300_bib3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.hoc.2004.03.008","article-title":"Biology of chronic myelogenous leukemia\u2014signaling pathways of initiation and transformation","volume":"18","author":"Melo","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"2022061702454645300_bib4","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"2022061702454645300_bib5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"2022061702454645300_bib6","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"2022061702454645300_bib7","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"2022061702454645300_bib8","first-page":"S37","article-title":"BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices","volume":"6","author":"Kantarjian","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"2022061702454645300_bib9","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"2022061702454645300_bib10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"2022061702454645300_bib11","first-page":"S11","article-title":"Resistance and relapse with imatinib in CML: causes and consequences","volume":"6","author":"Deininger","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"2022061702454645300_bib12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1365-2141.2008.07197.x","article-title":"Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease","volume":"142","author":"Valent","year":"2008","journal-title":"Br J Haematol"},{"key":"2022061702454645300_bib13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"2022061702454645300_bib14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"2022061702454645300_bib15","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"2022061702454645300_bib16","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"2022061702454645300_bib17","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","article-title":"Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia","volume":"7","author":"Weisberg","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"2022061702454645300_bib18","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.3324\/haematol.11369","article-title":"Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation","volume":"92","author":"Nicolini","year":"2007","journal-title":"Haematologica"},{"key":"2022061702454645300_bib19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"2022061702454645300_bib20","first-page":"534","article-title":"New tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"90","author":"Martinelli","year":"2005","journal-title":"Haematologica"},{"key":"2022061702454645300_bib21","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1158\/1078-0432.CCR-08-0117","article-title":"Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia","volume":"14","author":"Quint\u00e1s-Cardama","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022061702454645300_bib22","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.4161\/cc.5.24.3538","article-title":"Polo-like kinase 1: target and regulator of transcriptional control","volume":"5","author":"Martin","year":"2006","journal-title":"Cell Cycle"},{"key":"2022061702454645300_bib23","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/sj.onc.1208617","article-title":"Getting in and out of mitosis with Polo-like kinase-1","volume":"24","author":"Van Vugt","year":"2005","journal-title":"Oncogene"},{"key":"2022061702454645300_bib24","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1128\/MCB.26.6.2093-2108.2006","article-title":"Normal cells, but not cancer cells, survive severe Plk1 depletion","volume":"26","author":"Liu","year":"2006","journal-title":"Mol Cell Biol"},{"key":"2022061702454645300_bib25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrc1841","article-title":"Targeting polo-like kinase 1 for cancer therapy","volume":"6","author":"Strebhardt","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"2022061702454645300_bib26","doi-asserted-by":"crossref","first-page":"6895","DOI":"10.1158\/0008-5472.CAN-06-0358","article-title":"Polo-like kinase 1: target and regulator of anaphase-promoting complex\/cyclosome-dependent proteolysis","volume":"66","author":"Eckerdt","year":"2006","journal-title":"Cancer Res"},{"key":"2022061702454645300_bib27","doi-asserted-by":"crossref","first-page":"8555","DOI":"10.1074\/jbc.M710608200","article-title":"Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation","volume":"283","author":"Koida","year":"2008","journal-title":"J Biol Chem"},{"key":"2022061702454645300_bib28","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejphar.2008.06.062","article-title":"Evaluation of Polo-like kinase 1 inhibition on the G2\/M checkpoint in acute myelocytic leukaemia","volume":"591","author":"Didier","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"2022061702454645300_bib29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1593\/neo.07916","article-title":"Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles","volume":"10","author":"Sp\u00e4nkuch","year":"2008","journal-title":"Neoplasia"},{"key":"2022061702454645300_bib30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11596-008-0106-9","article-title":"Effect of antisense RNA targeting Polo-like kinase 1 on cell growth in A549 lung cancer cells","volume":"28","author":"Zhou","year":"2008","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"2022061702454645300_bib31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/1568026053507660","article-title":"Progress in the discovery of polo-like kinase inhibitors","volume":"5","author":"McInnes","year":"2005","journal-title":"Curr Top Med Chem"},{"key":"2022061702454645300_bib32","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.cub.2006.12.046","article-title":"The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1","volume":"17","author":"L\u00e9n\u00e1rt","year":"2007","journal-title":"Curr Biol"},{"key":"2022061702454645300_bib33","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.cub.2006.12.037","article-title":"BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo","volume":"17","author":"Steegmaier","year":"2007","journal-title":"Curr Biol"},{"key":"2022061702454645300_bib34","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood-2008-12-195867","article-title":"Polo-like kinase 1 is over-expressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells","volume":"114","author":"Renner","year":"2009","journal-title":"Blood"},{"key":"2022061702454645300_bib35","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood.V112.11.2973.2973","article-title":"Phase I\/II study of BI 2536, an intravenous Polo-like kinase-1 (Plk-1) inhibitor, in elderly patients with relapsed or refractory acute myeloid leukemia (AML): first results of a multi-center trial","volume":"112","author":"M\u00fcller-Tidow","year":"2008","journal-title":"Blood"},{"key":"2022061702454645300_bib36","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1200\/JCO.2008.16.1547","article-title":"Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors","volume":"26","author":"Mross","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022061702454645300_bib37","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1080\/1042819031000122033","article-title":"Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3\u03b2 pathways","volume":"44","author":"Sawafuji","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"2022061702454645300_bib38","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"key":"2022061702454645300_bib39","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1182\/blood-2006-11-055723","article-title":"Targeting of heat shock protein 32 (Hsp32)\/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib","volume":"111","author":"Mayerhofer","year":"2008","journal-title":"Blood"},{"key":"2022061702454645300_bib40","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1182\/blood-2004-02-0749","article-title":"Identification of mcl-1 as a BCR\/ABL-dependent target in chronic myeloid leukaemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides","volume":"105","author":"Aichberger","year":"2005","journal-title":"Blood"},{"key":"2022061702454645300_bib41","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1182\/blood.V95.6.2118","article-title":"STAT5 activation contributes to growth and viability in Bcr\/Abl-transformed cells","volume":"95","author":"Sillaber","year":"2000","journal-title":"Blood"},{"key":"2022061702454645300_bib42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"2022061702454645300_bib43","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.1038\/onc.2008.262","article-title":"Phosphorylation of Plk1 at Ser326 regulates its functions during mitotic progression","volume":"27","author":"Tang","year":"2008","journal-title":"Oncogene"},{"key":"2022061702454645300_bib44","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/sj.onc.1206200","article-title":"\u03b2-Hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1)","volume":"22","author":"Masuda","year":"2003","journal-title":"Oncogene"},{"key":"2022061702454645300_bib45","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1747-0285.2007.00594.x","article-title":"Selectivity-determining residues in Plk-1","volume":"70","author":"Kothe","year":"2007","journal-title":"Chem Biol Drug Des"},{"key":"2022061702454645300_bib46","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1182\/blood-2007-09-113175","article-title":"Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I","volume":"111","author":"Gontarewicz","year":"2008","journal-title":"Blood"},{"key":"2022061702454645300_bib47","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1097\/01.mlg.0000225895.40732.52","article-title":"STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro","volume":"116","author":"Wang-Rodriguez","year":"2006","journal-title":"Laryngoscope"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/70\/4\/1513\/2646927\/1513.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/70\/4\/1513\/2646927\/1513.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T07:28:27Z","timestamp":1655450907000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/70\/4\/1513\/563555\/Polo-like-Kinase-1-Plk1-as-a-Novel-Drug-Target-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,14]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2010,2,14]]},"published-print":{"date-parts":[[2010,2,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-09-2181","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6501623.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22386728","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22386728.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6501623","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22386731","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22386731.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,14]]}}}